SCHEMBL22950445

SCHEMBL22950445

COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)c(C(N)=O)n3)c2nc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 14/20 0.78
MERTK Q12866 8/20 0.78
MET P08581 9/20 0.55
KDR P35968 2/20 0.55
FLT1 P17948 2/20 0.55
AURKB Q96GD4 2/20 0.55
AURKA O14965 1/20 0.55
RIPK2 O43353 1/20 0.55
ABCB11 O95342 1/20 0.55
ABL1 P00519 1/20 0.55
EGFR P00533 1/20 0.55
ERBB2 P04626 1/20 0.55
NTRK1 P04629 1/20 0.55
LCK P06239 1/20 0.55
PGR P06401 1/20 0.55
LYN P07948 1/20 0.55
RET P07949 1/20 0.55
CHRM2 P08172 1/20 0.55
HCK P08631 1/20 0.55
ADRA2A P08913 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30537391 1.00 AXL (0.78) AXLMERTKMETKDRFLT1
SCHEMBL30537411 0.92 AXL (0.83) AXLMERTKMETKDRFLT1
SCHEMBL22949512 0.92 AXL (0.83) AXLMERTKMETKDRFLT1
SCHEMBL22949515 0.91 AXL (0.81) AXLMERTKMETKDRFLT1
SCHEMBL30537415 0.91 AXL (0.81) AXLMERTKMETKDRFLT1
SCHEMBL22950569 0.88 AXL (1.00) AXLMERTKMETKDRFLT1
SCHEMBL30537414 0.88 AXL (1.00) AXLMERTKMETKDRFLT1
SCHEMBL22950412 0.87 AXL (0.85) AXLMERTKMETKDRFLT1
SCHEMBL30537403 0.87 AXL (0.85) AXLMERTKMETKDRFLT1
SCHEMBL21219417 0.85 AXL (0.82) AXLMERTKMETKDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111936487-B Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2024-07-09 CN disclosed
US-11673897-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2023-06-13 US disclosed
US-11673897-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2023-06-13 US disclosed
US-20210032263-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2021-02-04 US disclosed
CN-111936487-A Compounds for the treatment of kinase-dependent disorders 埃克塞里艾克西斯公司 2020-11-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032263-A1 Compounds for the Treatment of Kinase-Dependent Disorders ERBB2, MAP3K6, PRKCH AXL 288/4885MERTK 22/4885MET 117/4885
US-11673897-B2 Compounds for the treatment of kinase-dependent disorders ERBB2, MAP3K6, PRKCH AXL 288/4885MERTK 22/4885MET 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.